drugset
Drugs / Recombinant Influenza Vaccine
last change Dec 2023 re-read 3 minutes ago

Recombinant Influenza Vaccine

also known as RIV4

Vaccine

Developed for
influenza
Investigated by
Sanofi Pasteur, a Sanofi Company · Brown University · Case Western Reserve University · Insight Therapeutics, LLC

Trials 2

today NCT05513391 · Ph 3 NCT03965195 · Ph 4
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT05513391 Nov 2022 → Oct 2023 — Sanofi Pasteur, a Sanofi Company Terminated No outcome recorded Stop: Business
Phase 41 trial · 1 missed
Phase 4 NCT03965195 Jul 2019 → Aug 2023 influenza Insight Therapeutics, LLC Unknown Missed primary

Press releases naming this drug 2 releases

DateIssuerRelease
2020-11-18 Sanofi European Commission approves Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗
2020-09-22 Sanofi CHMP recommends approval of Supemtek® (quadrivalent recombinant influenza vaccine) for the prevention of influenza in adults aged 18 years and older sanofi.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Recombinant Influenza Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT03965195 ↗
1

NCT05513391 ↗
Known as RIV4 “Biological: Recombinant influenza vaccine (RIV4)” NCT05513391 ↗
Modality Vaccine “quadrivalent recombinant influenza vaccine (RIV4, Flublok)” NCT03965195 ↗
Route Intramuscular “Route of administration: intramuscular” NCT05513391 ↗